Molecular Signatures of Gynecological Cancers: Clinicians Perspective | Zendy

TS Shylasree | Zendy; Bansal Richa | Zendy; Lavanya Gurram | Zendy; Seema Gulia | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Molecular Signatures of Gynecological Cancers: Clinicians Perspective

Author(s) -

TS Shylasree,

Bansal Richa,

Lavanya Gurram,

Seema Gulia

Publication year - 2021

Publication title -

indian journal of surgical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.231

H-Index - 16

eISSN - 0976-6952

pISSN - 0975-7651

DOI - 10.1007/s13193-020-01271-8

Subject(s) - surgical oncology , medicine , precision medicine , dna sequencing , personalized medicine , profiling (computer programming) , precision oncology , oncology , bioinformatics , computational biology , gene , pathology , biology , genetics , computer science , operating system

Large-scale molecular profiling and DNA sequencing has revolutionized cancer research. Precision medicine is a rapidly developing area in cancer care but it is not uniformly applied across different tumor types. Biomarker-based therapy is associated with improved outcomes, both in terms of progression-free survival and overall survival. Comprehensive genomic profiling (CGP) uses next-generation sequencing to analyze the complete coding sequence of hundreds of genes from a small amount of tissue. Genes included in these assays are those associated with cancer development or have diagnostic, prognostic, familial, or therapeutic implications Genomic profiling is emerging as a clinically viable tool to personalize patient's treatment. This article discusses how the insights gained through CGP can impact treatment plan in common gynecological cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research